Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

Similar articles for PubMed (Select 21211686)

3.

Pioglitazone induces regression of coronary atherosclerotic plaques in patients with type 2 diabetes mellitus or impaired glucose tolerance: a randomized prospective study using intravascular ultrasound.

Nakayama T, Komiyama N, Yokoyama M, Namikawa S, Kuroda N, Kobayashi Y, Komuro I.

Int J Cardiol. 2010 Jan 21;138(2):157-65. doi: 10.1016/j.ijcard.2008.08.031. Epub 2008 Sep 24.

PMID:
18817993
4.

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.

Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, Jure H, De Larochellière R, Staniloae CS, Mavromatis K, Saw J, Hu B, Lincoff AM, Tuzcu EM; PERISCOPE Investigators.

JAMA. 2008 Apr 2;299(13):1561-73. doi: 10.1001/jama.299.13.1561. Epub 2008 Mar 31.

PMID:
18378631
5.

Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus.

Davidson M, Meyer PM, Haffner S, Feinstein S, D'Agostino R Sr, Kondos GT, Perez A, Chen Z, Mazzone T.

Circulation. 2008 Apr 22;117(16):2123-30. doi: 10.1161/CIRCULATIONAHA.107.746610. Epub 2008 Apr 14.

6.

Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial.

Gerstein HC, Ratner RE, Cannon CP, Serruys PW, García-García HM, van Es GA, Kolatkar NS, Kravitz BG, Miller DM, Huang C, Fitzgerald PJ, Nesto RW; APPROACH Study Group.

Circulation. 2010 Mar 16;121(10):1176-87. doi: 10.1161/CIRCULATIONAHA.109.881003. Epub 2010 Mar 1.

7.

PERISCOPE: pioglitazone offers the right cluster of effects to confer benefit in type 2 diabetes.

[No authors listed]

Cardiovasc J Afr. 2008 May-Jun;19(3):159-62. No abstract available.

8.

Determinants of an optimal response to pioglitazone in terms of HDL-cholesterol.

Kabeya Y, Tomita M, Asai Y, Katsuki T, Oikawa Y, Meguro S, Shimada A, Atsumi Y.

Intern Med. 2011;50(8):825-31. Epub 2011 Apr 15.

9.

Long-term lipid effects of pioglitazone by baseline anti-hyperglycemia medication therapy and statin use from the PROactive experience (PROactive 14).

Spanheimer R, Betteridge DJ, Tan MH, Ferrannini E, Charbonnel B; PROactive Investigators.

Am J Cardiol. 2009 Jul 15;104(2):234-9. doi: 10.1016/j.amjcard.2009.03.023. Epub 2009 Jun 3.

PMID:
19576353
11.

CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone.

Betteridge DJ.

Fundam Clin Pharmacol. 2009 Dec;23(6):675-9. doi: 10.1111/j.1472-8206.2009.00741.x. Epub 2009 Sep 10. Review.

PMID:
19744248
12.

Correlation between high density lipoprotein-cholesterol and remodeling index in patients with coronary artery disease: IDEAS (IVUS diagnostic evaluation of atherosclerosis in Singapore)-HDL study.

Lee CH, Tai BC, Lim GH, Chan MY, Low AF, Tan KC, Chia BL, Tan HC.

Int J Cardiovasc Imaging. 2012 Jan;28(1):33-41. doi: 10.1007/s10554-010-9777-y. Epub 2011 Jan 1.

PMID:
21197580
13.

One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.

Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH; QUARTET Study Group.

Diabetes Care. 2004 Jan;27(1):141-7.

PMID:
14693980
15.

Effects of pioglitazone on the components of diabetic dyslipidaemia: results of double-blind, multicentre, randomised studies.

Khan M, Xu Y, Edwards G, Urquhart R, Mariz S.

Int J Clin Pract. 2004 Oct;58(10):907-12.

PMID:
15587767
16.

Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics.

Ratner RE, Cannon CP, Gerstein HC, Nesto RW, Serruys PW, Van Es GA, Kolatkar NS, Kravitz BG, Zalewski A, Fitzgerald PJ; APPROACH Study Group.

Am Heart J. 2008 Dec;156(6):1074-9. doi: 10.1016/j.ahj.2008.07.025. Epub 2008 Oct 11.

PMID:
19033001
17.

[Pioglitazone protects the type-2-diabetes patient from myocardial infarction and stroke].

[No authors listed]

MMW Fortschr Med. 2007 Aug 2;149(31-32):52-3. German. No abstract available.

PMID:
17849787
18.

Multiple risk factor intervention and progression of coronary atherosclerosis in patients with type 2 diabetes mellitus.

Kataoka Y, Shao M, Wolski K, Uno K, Puri R, Tuzcu EM, Nissen SE, Nicholls SJ.

Eur J Prev Cardiol. 2013 Apr;20(2):209-17. doi: 10.1177/2047487312437931. Epub 2012 Jan 31.

PMID:
22345692
19.
20.

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

J Clin Pharm Ther. 2006 Aug;31(4):375-83.

PMID:
16882108
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk